Overview

Treatment of Patients With Nocturia

Status:
Completed

Trial end date:
2010-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate a treatment of nocturia. The hypothesis is that SER120 will decrease the number of nocturic episodes compared to placebo.

Phase:

Phase 3

Details

Lead Sponsor:

Serenity Pharmaceuticals, Inc.